Skip to content
OpenCapital
Get started

ARS Pharmaceuticals, Inc. SPRY Investment Proceeds

Investment Proceeds at other companies

Viatris logo
ViatrisVTRS
——

Other financials

Income statement

See full
Revenue$22.7M+184%
Operating income-$60.1M-61.8%
Net income-$60.6M-78.6%
EPS (diluted)-$0.61-74.3%

Balance sheet

See full
Cash & equivalents$24.3M-39.0%
Total debt$96.5M+132,122%
Total equity$61.3M-73.2%
Total assets$287.6M-12.1%

Cash flow

See full
Operating cash flow-$44.9M-10.3%
CapEx--100%
Free cash flow-$44.9M-10.1%

Valuation

See full
Market cap$796.41M-48.7%
Enterprise value$868.61M-42.6%
P/S8.1×-7.9×

Profitability

See full
Operating margin-204.5%—
Net margin-200%-219pp
FCF margin-177.1%-206pp

Returns & leverage

See full
Return on equity-136.4%-144pp
Debt / equity1.6×+1.6×
Current ratio4.9×-6.1×

Where this comes from

Reported directly by ARS Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfShortTermInvestments.

The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about ARS Pharmaceuticals, Inc.'s investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ARS Pharmaceuticals, Inc.'s investment proceeds?
ARS Pharmaceuticals, Inc. (SPRY) reported investment proceeds of $42.5M in Q1 2026.
How has ARS Pharmaceuticals, Inc.'s investment proceeds changed year-over-year?
ARS Pharmaceuticals, Inc.'s investment proceeds decreased by 33.1% year-over-year, from $63.5M to $42.5M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.